Special access granted for rare gut disease treatment
NCT ID NCT05232110
Summary
This program provides special access to an investigational drug called pozelimab for patients with a rare, severe digestive disorder known as CD55-deficient protein-losing enteropathy. It is not a standard clinical trial but a pathway for individual patients to request the drug when no other treatments are suitable. The goal is to help control the disease in these specific, urgent cases.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CD55-DEFICIENT PROTEIN-LOSING ENTEROPATHY are added.
By submitting, you agree to our Terms of use
Conditions
Explore the condition pages connected to this study.